Market news — every asset we track

Assets

NKTX

Stifel reiterates Buy rating on Nkarta stock, cites trial progress

Sep 28Investing.com

Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance

Nkarta (NASDAQ:NKTX) said it expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology’s 2026 Convergence meeting in November, including presentations in myositis, scleroderma and program-wide safety. The company is developing an allogenei

Sep 27Yahoo Finance

NKTX

Nkarta at stifel forum: safer cell therapy push gains traction

Sep 23Investing.com

NKTX

Nkarta at H.C. Wainwright conference: autoimmune push gains focus

Sep 16Investing.com

NKTX

Nkarta to Participate in September Investor Conferences

Sep 10Yahoo Finance

NKTX

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

Two abstracts selected for oral presentations, highlighting investigational CAR-NK cell therapy’s clinical activity in idiopathic inflammatory myopathy and overall safety profile Third abstract selected for poster presentation highlighting NKX019’s clinical activity in systemic sclerosis SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune di

Sep 8Yahoo Finance

NKTX

Nkarta: 'Hold' NKX019 Discontinuation For R/R NHL And Pivot To Autoimmune Disorders

Sep 3Seeking Alpha

NKTX

Analysts Are Bullish on Top Healthcare Stocks: Idexx Laboratories (IDXX), Nkarta (NKTX)

Detailed price information for Idexx Laboratories (IDXX-Q) from The Globe and Mail including charting and trades.

Aug 15The Globe and Mail